Vertex spends billions on CRISPR technology in search of diabetes cure

A new billion-dollar agreement with US gene editing firm Arbor Biotechnologies marks a continuation of biotech company Vertex's efforts to develop stem cell treatments, with a special focus on diabetes.

Photo: Brian Snyder/Reuters/Ritzau Scanpix

US-based biotech company Vertex, known for its specialization within cystic fibrosis, has also been working towards a breakthrough for treating type 1 diabetes over the past few years. That innovation is now a step closer.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs